LEXX
Lexaria Bioscience Corp.
Key Financials
Operating Income
$-11880737
↓ 106.5%
Net Income
$-11901841
↓ 105.4%
Revenue
$705923
↑ 52.0%
Total Assets
$4.2M
↓ 52.9%
Shareholders' Equity
$3.0M
↓ 62.8%
EPS (Diluted)
$-0.66
↓ 40.4%
Gross Profit
$703203
↑ 53.1%
Total Liabilities
$1.6M
↑ 30.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 4/13/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| 8-K | 2/6/2026 | View on SEC |
| 8-K | 1/28/2026 | View on SEC |
| S-8 | 1/28/2026 | View on SEC |
| EFFECT | 1/14/2026 | View on SEC |
| 424B3 | 1/14/2026 | View on SEC |
| 25-NSE | 1/14/2026 | View on SEC |
| 10-Q | 1/13/2026 | View on SEC |
| S-3 | 12/29/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LEXX |
| Company Name | Lexaria Bioscience Corp. |
| CIK | 1348362 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0831 |
| State of Incorporation | NV |
| Phone | 250-765-6424 |